Vivos Therapeutics (VVOS) Free Cash Flow (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Free Cash Flow data on file, last reported at -$6.0 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$6.0 million, down 53.85% year-over-year; the trailing twelve-month figure through Mar 2026 was -$22.6 million (down 55.47% YoY), and the FY2025 annual result was -$20.4 million, down 54.22% from the prior year.
• Free Cash Flow advanced to -$6.0 million in Q1 2026 per VVOS's latest filing, from -$8.1 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$2.1 million in Q4 2023 and troughed at -$8.1 million in Q4 2025.
• A 5-year average of -$4.2 million and a median of -$3.9 million in 2025 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow soared 50.77% in 2023, then plunged 162.09% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$3.2 million in 2022, then jumped by 33.73% to -$2.1 million in 2023, then plunged by 47.02% to -$3.1 million in 2024, then slumped by 162.09% to -$8.1 million in 2025, then gained by 25.93% to -$6.0 million in 2026.
• Business Quant data shows VVOS's Free Cash Flow at -$6.0 million in Q1 2026, -$8.1 million in Q4 2025, and -$4.1 million in Q3 2025.